X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Elder Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs ELDER PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. ELDER PHARMA FRESENIUS KABI ONCO./
ELDER PHARMA
 
P/E (TTM) x 22.1 -0.2 - View Chart
P/BV x 3.1 0.1 3,084.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   ELDER PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
ELDER PHARMA
Jun-14
FRESENIUS KABI ONCO./
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs176380 46.3%   
Low Rs79188 41.8%   
Sales per share (Unadj.) Rs37.7491.2 7.7%  
Earnings per share (Unadj.) Rs5.1-3.2 -160.1%  
Cash flow per share (Unadj.) Rs6.714.4 46.7%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5376.5 11.3%  
Shares outstanding (eoy) m158.2320.54 770.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.6 584.0%   
Avg P/E ratio x25.0-89.3 -28.0%  
P/CF ratio (eoy) x18.919.7 96.0%  
Price / Book Value ratio x3.00.8 396.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1355,833 345.2%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7032,179 32.3%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96310,089 59.1%  
Other income Rs m18257 7.0%   
Total revenues Rs m5,98110,346 57.8%   
Gross profit Rs m1,430-792 -180.6%  
Depreciation Rs m258361 71.4%   
Interest Rs m-262,756 -0.9%   
Profit before tax Rs m1,216-3,653 -33.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-683,713 -1.8%   
Tax Rs m342125 273.4%   
Profit after tax Rs m806-65 -1,233.2%  
Gross profit margin %24.0-7.8 -305.6%  
Effective tax rate %28.1-3.4 -821.3%   
Net profit margin %13.5-0.6 -2,086.5%  
BALANCE SHEET DATA
Current assets Rs m5,1029,240 55.2%   
Current liabilities Rs m2,3859,998 23.9%   
Net working cap to sales %45.6-7.5 -606.5%  
Current ratio x2.10.9 231.4%  
Inventory Days Days15046 324.0%  
Debtors Days Days11360 189.0%  
Net fixed assets Rs m5,14810,124 50.9%   
Share capital Rs m158206 76.9%   
"Free" reserves Rs m6,5565,582 117.4%   
Net worth Rs m6,7327,734 87.0%   
Long term debt Rs m9524,889 19.5%   
Total assets Rs m10,38822,882 45.4%  
Interest coverage x-45.8-0.3 14,072.6%   
Debt to equity ratio x0.10.6 22.4%  
Sales to assets ratio x0.60.4 130.2%   
Return on assets %7.511.8 63.8%  
Return on equity %12.0-0.8 -1,416.7%  
Return on capital %14.622.3 65.5%  
Exports to sales %74.53.0 2,450.5%   
Imports to sales %24.80.4 5,799.7%   
Exports (fob) Rs m4,441307 1,448.3%   
Imports (cif) Rs m1,47743 3,427.8%   
Fx inflow Rs m5,298307 1,727.9%   
Fx outflow Rs m1,772125 1,414.4%   
Net fx Rs m3,525181 1,944.5%   
CASH FLOW
From Operations Rs m1,27411,754 10.8%  
From Investments Rs m-1,204-561 214.8%  
From Financial Activity Rs m-196-6,762 2.9%  
Net Cashflow Rs m-1264,432 -2.8%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 7.5 4.0%  
FIIs % 9.6 16.8 57.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.1 25.2%  
Shareholders   42,599 16,479 258.5%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   IPCA LABS  NOVARTIS  ALEMBIC PHARMA  MERCK LTD  SANOFI INDIA  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS